Medicenna shareholders back director slate, auditor and share consolidation

Medicenna Therapeutics Corp. said shareholders approved three items at its annual general and special meeting on 1/10/2026: all nominated directors were elected, MNP LLP was re-appointed as auditor and a share consolidation was authorised within a board-set range. The company said 31,82% of its issued and outstanding common shares were represented in person or by proxy.

The four nominees on the management information circular dated 19/8/2026 all won with more than 97% of votes cast. Mr. Albert Beraldo received 27.751.517 votes for and 736.191 against, Mr. Richard Sutin 27.779.927 for and 707.781 against, Mr. Angelos Georgakis 27.779.495 for and 708.213 against, and Dr. Fahar Merchant 27.715.844 for and 771.864 against.

For shareholders, the most notable item was the special resolution on a consolidation of the company’s issued and outstanding common shares. Medicenna said the board can choose the ratio, which must fall between one post-consolidation share for every 2 to 20 pre-consolidation shares, and can also decide not to proceed.

The company said the consolidation may form part of its review of strategic opportunities, including, if appropriate, support for compliance with the listing requirements of a major U.S. stock exchange. Medicenna also said that, if implemented, the move could increase the trading price per common share and help meet minimum bid price requirements, while potentially making the shares more attractive to U.S. institutional investors and other investors subject to minimum share-price rules.

If the board decides to move ahead, Medicenna said it will announce the applicable ratio and effective date after receiving required regulatory approvals. The company added that a consolidation would not guarantee that a U.S. listing application, if pursued, would satisfy all listing requirements or be accepted.